SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NKTR Drug delivery Company
NKTR 56.70+5.1%Nov 14 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Arthur Radley who wrote (123)9/14/2006 12:00:38 PM
From: Ian@SI  Read Replies (1) of 507
 
Cary,

I agree that an oral INSULIN product would kill Exubera. EMIS, which has been all talk and no drugs, claims to have one in their pipeline. I don't know that the MRK or NVS products would be a substitute for insulin in diabetics needing that drug; or the extent to which they might replace the insulin need in some diabetics.

As has been the case for any tx, sooner or later something better comes along.

Ian
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News